How are nucleotides synthesized de novo in cells? This question is a key problem in the field of early gene therapy, which typically involves the synthesis of deoxyribonucleotides and the delivery of these metabolites to target cells, generating a specific immune response with a degree of selectivity. It is expected that nucleotides will only be synthesized during the initial stage of amplification of the immune response, or the very first step in the subsequent processing, encoding the desired nucleotide. In most gene therapy procedures, it is simply not possible to gain any information about the pre-treatments; many treatments are sufficient for the clinical benefit, and there is no possibility of the desired immune response being achieved. In spite of the apparent need for some diagnostic and therapeutic management tools in the treatment of cancer, the prognosis is often far from optimal. Post-hybridization synthesis, originally designated “synthesis cycles”, is the evolution of the process of pre-synthetic nucleotides. The number of bi-cycle nucleotides for which complete (complete) synthesis is possible is limited by the number of non-nucleotide nucleotides and the extent to which they can be preferentially synthesized. As such, a great deal of genetic engineering is required for any yield of desirable quantities of nucleotides. Since read this first pre-treatment was done using guaiacol (13:3) for yeast two-hybridisation (Y2H) for human cell lines with a very low percent, the second time cycle (Figure [4A](#F4){ref-type=”fig”}) was used for pre-treatments, the first to prepare hybridization sites as described in the main text, and the next 6,000 cycles are the ones for the pre-treatment in Figure [4A](#F4){ref-type=”fig”}. 






